Immunology Investor Event
Parallel studies to address
both Type 2 and non-Type 2 COPD
DUPIXENT
(dupilumab) Injection 300mg
itepekimab
first-in-class
anti-IL-33
sanofi
Itepekimab Phase 3 and DupixentⓇ Phase 3 in COPD are targeting
two distinct populations with minimal overlap
2021
2022
Boreas
Notus
Aerify 1
2023
2024
Ambition to lead in COPD with two
complementary assets, DupixentⓇ and
itepekimab, with potential to deliver
first-in-class and best-biologic efficacy
Itepekimab pivotal program addresses
an additional 40% of COPD patients not
targeted by DupixentⓇ
Opportunity to lead the science of
emerging COPD endotypes (e.g. former
smokers/frequent exacerbators)
U.S. Expected Submission:
EU Expected Submission
40 Immunology Investor Event
Aerify 2
LPI achieved in Feb 2022 for BoreasView entire presentation